Suppr超能文献

桥本甲状腺炎合并甲状腺乳头状癌中央区淋巴结转移的综合预测模型:BRAF 可能不是一个有价值的预测指标。

A comprehensive prediction model for central lymph node metastasis in papillary thyroid carcinoma with Hashimoto's thyroiditis: BRAF may not be a valuable predictor.

机构信息

Department of Medical Ultrasound, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.

出版信息

Front Endocrinol (Lausanne). 2024 Sep 19;15:1429382. doi: 10.3389/fendo.2024.1429382. eCollection 2024.

Abstract

PURPOSE

Papillary thyroid carcinoma (PTC) frequently coexists with Hashimoto's thyroiditis (HT), which poses challenges in detecting central lymph node metastasis (CLNM) and determining optimal surgical management. Our study aimed to identify the independent predictors for CLNM in PTC patients with HT and develop a comprehensive prediction model for individualized clinical decision-making.

PATIENTS AND METHODS

In this retrospective study, a total of 242 consecutive PTC patients who underwent thyroid surgery and central lymph node dissection between February 2019 and December 2021 were included. 129 patients with HT were enrolled as the case group and 113 patients without HT as control. The results of patients' general information, laboratory examination, ultrasound features, pathological evaluation, and BRAF mutation were collected. Multivariate logistic regression analysis was used to identify independent predictors, and the prediction model and nomogram were developed for PTC patients with HT. The performance of the model was assessed using the receiver operating characteristic curve, calibration curve, decision curve analysis, and clinical impact curve. In addition, the impact of the factor BRAF mutation was further evaluated.

RESULTS

Multivariate analysis revealed that gender (OR = 8.341, P = 0.013, 95% CI: 1.572, 44.266), maximum diameter (OR = 0.316, P = 0.029, 95% CI: 0.113, 0.888), multifocality (OR = 3.238, P = 0.010, 95% CI: 1.319, 7.948), margin (OR = 2.750, P = 0.046, 95% CI: 1.020, 7.416), and thyrotropin receptor antibody (TR-Ab) (OR = 0.054, P = 0.003, 95% CI: 0.008, 0.374) were identified as independent predictors for CLNM in PTC patients with HT. The area under the curve of the model was 0.82, with accuracy, sensitivity, and specificity of 77.5%, 80.3% and 75.0%, respectively. Meanwhile, the model showed satisfactory performance in the internal validation. Moreover, the results revealed that BRAF mutation cannot further improve the efficacy of the prediction model.

CONCLUSION

Male, maximum diameter > 10mm, multifocal tumors, irregular margin, and lower TR-Ab level have significant predictive value for CLNM in PTC patients with HT. Meanwhile, BRAF mutation may not have a valuable predictive role for CLNM in these cases. The nomogram constructed offers a convenient and valuable tool for clinicians to determine surgical decision and prognostication for patients.

摘要

目的

甲状腺乳头状癌(PTC)常与桥本甲状腺炎(HT)共存,这给中央淋巴结转移(CLNM)的检测和确定最佳手术管理带来了挑战。本研究旨在确定 HT 合并 PTC 患者 CLNM 的独立预测因素,并为个体化临床决策制定综合预测模型。

患者和方法

本回顾性研究纳入了 2019 年 2 月至 2021 年 12 月期间接受甲状腺手术和中央淋巴结清扫术的 242 例连续 PTC 患者。其中 129 例 HT 患者为病例组,113 例无 HT 患者为对照组。收集患者的一般信息、实验室检查、超声特征、病理评估和 BRAF 突变结果。采用多变量逻辑回归分析确定独立预测因素,并为 HT 合并 PTC 患者建立预测模型和列线图。采用受试者工作特征曲线、校准曲线、决策曲线分析和临床影响曲线评估模型的性能。此外,还进一步评估了 BRAF 突变因素的影响。

结果

多因素分析显示,性别(OR=8.341,P=0.013,95%CI:1.572,44.266)、最大直径(OR=0.316,P=0.029,95%CI:0.113,0.888)、多灶性(OR=3.238,P=0.010,95%CI:1.319,7.948)、边缘(OR=2.750,P=0.046,95%CI:1.020,7.416)和促甲状腺素受体抗体(TR-Ab)(OR=0.054,P=0.003,95%CI:0.008,0.374)是 HT 合并 PTC 患者 CLNM 的独立预测因素。模型的曲线下面积为 0.82,准确性、敏感度和特异度分别为 77.5%、80.3%和 75.0%。同时,模型在内部验证中表现良好。此外,结果表明 BRAF 突变不能进一步提高预测模型的疗效。

结论

男性、最大直径>10mm、多灶性肿瘤、不规则边缘和较低的 TR-Ab 水平对 HT 合并 PTC 患者的 CLNM 具有显著的预测价值。同时,BRAF 突变对这些病例的 CLNM 可能没有有价值的预测作用。所构建的列线图为临床医生确定手术决策和预测患者预后提供了便捷而有价值的工具。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验